| Primary | Number of Participants Who Experience One or More Bleeding Related Adverse Events (AE) | Bleeding related AEs include any sign or symptom of bleeding, even if not requiring intervention by a medical/healthcare professional, as well as clinically-relevant non major bleeding or major bleeding. | The analysis population included all participants who received ≥1 dose of MK-2060. | Posted | | Count of Participants | | Participants | | Up to approximately 104 days | | | | ID | Title | Description |
|---|
| OG000 | MK-2060 | Participants continued their established background therapy of daily 75 mg clopidogrel for 2 weeks (days -14 to 0). Participants then continued background therapy while receiving 25 mg MK-2060 intravenous (IV) infusion on days 1, 3, 5, and 8. |
| | | Title | Denominators | Categories |
|---|
| | |
| |
| Primary | Number of Participants Who Experience One or More AEs | An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. | The analysis population included all participants who received ≥1 dose of MK-2060. | Posted | | Count of Participants | | Participants | | Up to approximately 104 days | | | | ID | Title | Description |
|---|
| OG000 | MK-2060 | Participants continued their established background therapy of daily 75 mg clopidogrel for 2 weeks (days -14 to 0). Participants then continued background therapy while receiving 25 mg MK-2060 intravenous (IV) infusion on days 1, 3, 5, and 8. |
| |
| Primary | Number of Participants Who Discontinue Study Intervention Due to an AE | An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. | The analysis population included all participants who received ≥1 dose of MK-2060. | Posted | | Count of Participants | | Participants | | Up to approximately 8 days | | | | ID | Title | Description |
|---|
| OG000 | MK-2060 | Participants continued their established background therapy of daily 75 mg clopidogrel for 2 weeks (days -14 to 0). Participants then continued background therapy while receiving 25 mg MK-2060 intravenous (IV) infusion on days 1, 3, 5, and 8. |
| |
| Secondary | Area Under the Concentration-Time Curve From 0 to 168 Hours (AUC0-168) of MK-2060 | The AUC0-168 was defined as the area under the concentration-time curve of MK-2060 in plasma from time zero to 168 hours after administration. The Week 1 value is the extrapolated value using data up to 48 hours postdose Day 1, with the "Partial area" option in WinNonlin software using a Start time of 0 hours and an End time of 168 hours. Week 2 value included data for Day 8: predose, and 1, 12, 24, 48, 96, and 168 hours postdose. | The analysis population included all participants who received ≥1 dose of MK-2060 and who complied with the protocol sufficiently to ensure that the data are likely to exhibit the effects of treatment according to the underlying scientific model. | Posted | | Geometric Mean | Geometric Coefficient of Variation | hour*nmol/L | | Day 1: predose, and 1, 12, 24, and 48 hours postdose. Day 8: predose, and 1, 12, 24, 48, 96, and 168 hours postdose. | | | | ID | Title | Description |
|---|
| OG000 | MK-2060 | Participants continued their established background therapy of daily 75 mg clopidogrel for 2 weeks (days -14 to 0). Participants then continued background therapy while receiving 25 mg MK-2060 intravenous (IV) infusion on days 1, 3, 5, and 8. |
| |
| Secondary | Maximum Plasma Concentration (Cmax) of MK-2060 | Cmax was defined as the maximum concentration of MK-2060 observed in plasma after administration. Week 2 value included data for Day 8: predose and 1, 12, 24, 48, 96, and 168 hours postdose. | The analysis population included all participants who received ≥1 dose of MK-2060 and who complied with the protocol sufficiently to ensure that the data are likely to exhibit the effects of treatment according to the underlying scientific model. | Posted | | Geometric Mean | Geometric Coefficient of Variation | nmol/L | | Day 1: predose, and 1, 12, and 48 hours postdose. Day 8: predose, and 1, 12, and 24 hours postdose; and once daily on Days 10, 12, 15, 21, 29, 35, 49, 67, and 104. | | | | ID | Title | Description |
|---|
| OG000 | MK-2060 | Participants continued their established background therapy of daily 75 mg clopidogrel for 2 weeks (days -14 to 0). Participants then continued background therapy while receiving 25 mg MK-2060 intravenous (IV) infusion on days 1, 3, 5, and 8. |
| |
| Secondary | Plasma Concentration at 168 Hours (C168) of MK-2060 | C168 was defined as the concentration of MK-2060 observed in plasma 168 hours after administration. Week 2 value included data for Day 8: 168 hours postdose. | The analysis population included all participants who received ≥1 dose of MK-2060 and who complied with the protocol sufficiently to ensure that the data are likely to exhibit the effects of treatment according to the underlying scientific model. | Posted | | Geometric Mean | Geometric Coefficient of Variation | nmol/L | | Days 1 and 8: 168 hours post-dose | | | | ID | Title | Description |
|---|
| OG000 | MK-2060 | Participants continued their established background therapy of daily 75 mg clopidogrel for 2 weeks (days -14 to 0). Participants then continued background therapy while receiving 25 mg MK-2060 intravenous (IV) infusion on days 1, 3, 5, and 8. |
| |
| Secondary | Time to Maximum Plasma Concentration (Tmax) of MK-2060 | Tmax was defined as the time required to reach the maximum concentration of MK-2060 observed in plasma after administration. Week 2 value included data for Day 8: predose and 1, 12, 24, 48, 96, and 168 hours postdose. | The analysis population included all participants who received ≥1 dose of MK-2060 and who complied with the protocol sufficiently to ensure that the data are likely to exhibit the effects of treatment according to the underlying scientific model. | Posted | | Median | Full Range | Hours | | Day 1: predose, and 1, 12, and 48 hours postdose. Day 8: predose, and 1, 12, and 24 hours postdose; and once daily on Days 10, 12, 15, 21, 29, 35, 49, 67, and 104. | | | | ID | Title | Description |
|---|
| OG000 | MK-2060 | Participants continued their established background therapy of daily 75 mg clopidogrel for 2 weeks (days -14 to 0). Participants then continued background therapy while receiving 25 mg MK-2060 intravenous (IV) infusion on days 1, 3, 5, and 8. |
| |
| Secondary | Terminal Half Life (t1/2) of MK-2060 | T1/2 was defined as the time required to divide the MK-2060 plasma concentration by two after reaching pseudo-equilibrium. | The analysis population included all participants who received ≥1 dose of MK-2060 and who complied with the protocol sufficiently to ensure that the data are likely to exhibit the effects of treatment according to the underlying scientific model. | Posted | | Geometric Mean | Geometric Coefficient of Variation | Hours | | Day 8: predose, and 1, 12, and 24 hours postdose. Once daily on Days 10, 12, 15, 21, 29, 35, 49, 67, and 104. | | | | ID | Title | Description |
|---|
| OG000 | MK-2060 | Participants continued their established background therapy of daily 75 mg clopidogrel for 2 weeks (days -14 to 0). Participants then continued background therapy while receiving 25 mg MK-2060 intravenous (IV) infusion on days 1, 3, 5, and 8. |
| |
| Secondary | Clearance at Steady State (CLss) of MK-2060 | CLss was defined as the volume of plasma from which MK-2060 was eliminated per unit time following administration, once at steady state. | The analysis population included all participants who received ≥1 dose of MK-2060 and who complied with the protocol sufficiently to ensure that the data are likely to exhibit the effects of treatment according to the underlying scientific model. | Posted | | Geometric Mean | Geometric Coefficient of Variation | L/hour | | Day 8: predose, and 1, 12, and 24 hours postdose. Once daily on Days 10, 12, 15, 21, 29, 35, 49, 67, and 104. | | | | ID | Title | Description |
|---|
| OG000 | MK-2060 | Participants continued their established background therapy of daily 75 mg clopidogrel for 2 weeks (days -14 to 0). Participants then continued background therapy while receiving 25 mg MK-2060 intravenous (IV) infusion on days 1, 3, 5, and 8. |
| |
| Secondary | Apparent Volume of Distribution at Steady State (Vss) of MK-2060 | Vss was defined as the volume of plasma that would be necessary to contain the total amount of administered MK-2060 at the same concentration that MK-2060 was observed in the blood plasma after reaching steady state. | The analysis population included all participants who received ≥1 dose of MK-2060 and who complied with the protocol sufficiently to ensure that the data are likely to exhibit the effects of treatment according to the underlying scientific model. | Posted | | Geometric Mean | Geometric Coefficient of Variation | Liters | | Day 8: predose, and 1, 12, and 24 hours postdose. Once daily on Days 10, 12, 15, 21, 29, 35, 49, 67, and 104. | | | | ID | Title | Description |
|---|
| OG000 | MK-2060 | Participants continued their established background therapy of daily 75 mg clopidogrel for 2 weeks (days -14 to 0). Participants then continued background therapy while receiving 25 mg MK-2060 intravenous (IV) infusion on days 1, 3, 5, and 8. |
| |
| Secondary | Time to Hemostasis Following MK-2060 Treatment | Time to hemostasis is assessed by measuring the time that pressure is held from removal of dialysis catheters from the dialysis access site [i.e., arteriovenous (AV) fistula or AV graft] until adequate hemostasis has been obtained for both the arterial and venous sites. | The analysis population included all participants who received ≥1 dose of MK-2060 and who complied with the protocol sufficiently to ensure that the data are likely to exhibit the effects of treatment according to the underlying scientific model. | Posted | | Mean | 95% Confidence Interval | Minutes | | Up to approximately 15 days | | | | ID | Title | Description |
|---|
| OG000 | MK-2060 | Participants continued their established background therapy of daily 75 mg clopidogrel for 2 weeks (days -14 to 0). Participants then continued background therapy while receiving 25 mg MK-2060 intravenous (IV) infusion on days 1, 3, 5, and 8. |
| |